11.3% Return Seen to Date on SmarTrend Quest Diagnostics Call (DGX)
Comtex SmarTrend(R) - Wed Apr 16, 11:04AM CDT
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
Equities to Watch in the Health Care Sector -- Research on Novadaq Technologies, Quest Diagnostics, Cooper Cos, and AcelRx Pharma
PR Newswire - Tue Apr 15, 11:56AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,173.24, up 0.91% and the NASDAQ Composite closed at 4,022.69, up 0.57%. The S&P 500 finished the session 0.82% higher at 1,830.61. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 648.05, up 0.51%, while the same has declined 3.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Novadaq Technologies Inc. (NASDAQ: NVDQ), Quest Diagnostics Inc. (NYSE: DGX), The Cooper Cos Inc. (NYSE: COO) and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free technical research on NVDQ, DGX, COO and ACRX can be downloaded upon signing up at:
The Zacks Analyst Blog Highlights: Quest Diagnostics, Vornado Realty Trust, Equity One, Simon Property Group and Duke Realty
PR Newswire - Tue Apr 15, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Quest Diagnostics Inc. (NYSE
Addus HomeCare (PAL) Crumbles: Stock Drops 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 8:15AM CDT
Addus HomeCare’s shares fell over 5% yesterday, breaking its one-month volatile trading range
RadNet (RDNT) in Focus: Stock Adds 8.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:37AM CDT
RadNet, Inc. was a big mover last session, as the company saw its shares rise more than 8% on the day.
Clinical Laboratory Services Market 2013-2018: Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles
M2 - Tue Apr 15, 5:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d98zpd/clinical) has announced the addition of the "Clinical Laboratory Services - Markets, Growth Opportunities, Competitive Analysis and Competitor Profiles" report to their offering. The Clinical Laboratory Services estimates the market at $99.1 billion for 2013, up 1.3% from the estimated value in 2008 of $92.7 billion. Faced with daunting reimbursement cuts and other challenges, the world market for clinical laboratory services grew just over one percent in the past five year. The report notes that while there are a number of drivers for this market: aging populations, a growing incidence of chronic diseases, increasing emphasis on diagnosis and disease monitoring, and a growth in advanced testing technologies and practices. However, there are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions, and these are dampening growth. In the United States, the U.S. Congress ultimately has the responsibility to adjust the Medicare fee schedule according to economic factors, including controlling costs, monitoring utilization, and ensuring adequate delivery of health care services. The passing of the Patient Protection and Affordable Care Act generated a number of provisions on laboratory fee schedules, mostly in the direction of reductions. These reductions were effective starting 2011 and will continue to be adjusted through 2015. Medicare has slashed reimbursement amounts for many common tests such as Vitamin B12, triglycerides and glucose nearly six percent between 2009 and 2013. Some tests, such as total iron or aluminum tests have been cut 19% and 30% respectively during that period. Bio-Reference Laboratories, Quest, Lab Corp, Myriad, and Spectra are among the leaders in the industry. Quest Diagnostics and LabCorp have advantages in the market due to the wide exposure, large number of locations, and greater financial positions. Smaller, independent laboratories may find it difficult to keep up with the fast changing industry largely due to limited financial abilities to invest in new technologies and testing services. Some laboratories, such as Bio-Reference Labs have found success in operating on a regional basis while companies such as Myriad Genetics and Genomic Health remain competitive by focusing on more specialized genetic-based testing. Key Topics Covered: 1. Executive Summary 2. Industry Overview 3. CLIA Laboratory Registration, Laboratories By Type 4. Leading Market Participants 5. Market Trends And Summary Companies Mentioned - Bio-Reference Laboratories - Clarient, Inc. - DaVita - Genomic Health - Genoptix, Inc. - Genzyme Corporation - Laboratory Corporation of America (LabCorp) - Quest Diagnostics, Inc. - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/d98zpd/clinical
Quest Diagnostics Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:32PM CDT
Adjusted earnings per share of Quest Diagnostic came in at $1.03, beating the Zacks Consensus Estimate of 94 cents by 9.6%, and exceeding the company's prior-year earnings by 2%.
Laboratory Service Providers Should Profit From This New Revenue Source
Bob Chandler, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Medical testing leaders such as Laboratory Corporation of America and Quest Diagnostics have disappointed investors with little to no sales and profit growth over the past couple years. Sluggish demand and collapsing prices have smothered...
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.
Gentiva Health Slumps: GTIV Falls 6.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:33AM CDT
Shares of Gentiva Health fell over 6% on the day. This breaks the recent trend of the company, as the stock is now trading below the volatile price range of $8.5 to $9.5 in the past one-month time frame. This home health services provider company has seen a flat track record when it comes to current year estimate revisions.
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
CombiMatrix Names Trilochan Sahoo, M.D., Director of Cytogenetics
GlobeNewswire - Wed Apr 09, 5:00AM CDT
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, today announced that Trilochan Sahoo, M.D. FACMG, has recently joined the Company as Director of Cytogenetics. Dr. Sahoo will report to Wes Tyson, M.D., Chief Medical Officer of CombiMatrix.
Healthcare Companies Report Recognitions, Schedules, and Stock Movements - Analyst Notes on WellPoint, Quest Diagnostics, LabCorp, Covance, and Masimo
PR Newswire - Tue Apr 08, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding WellPoint Inc. (NYSE: WLP), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corp. of America Holdings (NYSE: LH), Covance Inc. (NYSE: CVD), and Masimo Corporation (NASDAQ: MASI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Patients Nationwide Now Have Direct Access to Lab Test Results through Quest Diagnostics
PR Newswire - Mon Apr 07, 11:46AM CDT
For the first time, Americans nationwide can directly access their personal laboratory data through Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Quest Diagnostics provides diagnostic information services to about 30% of American adults each year.
Walgreen, Water Street Sign Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 2:20PM CDT
Walgreen has signed a definitive agreement with Water Street.
Better Buy: Laboratory Corp Vs. Quest Diagnostics
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 03, 9:58PM CDT
Lab services may not be the first investment idea you consider when thinking about warm weather plays, but maybe it should be. Major lab services plays Laboratory Corp and Quest Diagnostics both remind investors in their annual reports that...
Quest Diagnostics To Release First Quarter 2014 Financial Results On April 24
PR Newswire - Thu Apr 03, 4:19PM CDT
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2014 results on Thursday, April 24, 2014, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
Myriad Genetics Jumps on Medicare Decision - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 1:50PM CDT
Shares of Myriad Genetics gained 11.47% on yesterday's close.
When Harsh Medicare Cuts Are Cause for Celebration
David Williamson, The Motley Fool - Motley Fool - Wed Apr 02, 6:53PM CDT
Another of today's winners in the health-care space is Myriad Genetics , up 11% today after Medicare reimbursement cuts were announced. Though the cuts were harsh, they were lower than the market had been fearing, and Myriad came out on top as a...